Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorStanford University

About this trial

The investigators are studying the pathophysiologic links between obesity, insulin resistance (IR), adipose tissue infection, and post-acute sequelae of COVID-19 (PASC). This study looks at whether adipose (fat) tissue contributes to PASC by driving chronic inflammation or by serving as a reservoir for SARS-CoV-2 persistence. The results will not only determine whether obesity and IR are risk factors for PASC, but will also define fundamental biology that sets the stage for the investigation of novel or existing therapies that target the causal pathways identified.

Eligibility criteria

Qualifiers

Ages 18 to 80

BMI ≥ 25 kg/m2

not currently pregnant

Disqualifiers

pregnancy

prior liposuction

recent change in weight (> 2 kg in one month)

bleeding disorders

Trial design

Treatments tested in this trial

  • Adipose Tissue Biopsy
  • Steady State Plasma Glucose (SSPG) Test

Treatment groups

55 Participants
are divided into 3 treatment groups

Sponsors and collaborators